Adenosine Receptor (A1/A2A) Neurons

Adenosine Receptor Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine Receptor (A1/A2A) Neurons</th>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
</table>

Introduction

Adenosine Receptor (A1 A2A) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Adenosine Receptor Neurons

<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Adenosine Receptor (A1/A2A) Neurons</th>
</tr>
<tr>
<td class="label">Database</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000197](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)</td>
</tr>
</table>

Introduction

Adenosine Receptor (A1 A2A) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Adenosine receptor neurons are neurons that express adenosine receptors (A1, A2A, A2B, and A3) on their surface, making them responsive to adenosine signaling in the central nervous system. These receptors play crucial roles in regulating sleep-wake cycles, motor control, neuroprotection, and cognitive function. Adenosine receptors, particularly the A1 and A2A subtypes, have emerged as important therapeutic targets in neurodegenerative diseases, with A2A receptor antagonists like istradefylline approved for Parkinson's disease treatment. [@fredholm2020]

<!-- multi-taxonomy-enrichment --> [@ribeiro2019]

<!-- taxonomy-enrichment --> [@kalia2018]

Taxonomy & Classification

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)

Multi-Taxonomy Classification

Taxonomy Database Cross-References

External Database Links

• [Cell Ontology (CL:0000197)](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000197)
• [OBO Foundry (CL:0000197)](http://purl.obolibrary.org/obo/CL_0000197)
• [Allen Brain Cell Atlas](https://portal.brain-map.org/atlases-and-data/bkp/abc-atlas)
• [CellxGene Census](https://cellxgene.cziscience.com/)
• [Human Cell Atlas](https://www.humancellatlas.org/)

Anatomy and Distribution

A1 Adenosine Receptor

The A1 adenosine receptor (A1R) is widely distributed throughout the central nervous system:

• Cerebral cortex: Highest density in cortical layers I and II
• Hippocampus: Particularly in CA1 and dentate gyrus regions
• Cerebellum: Purkinje cell layer and molecular layer
• Thalamus: Relay nuclei and reticular nucleus
• Spinal cord: Dorsal horn, particularly laminae I-II
• Peripheral nervous system: Sensory ganglia

A2A Adenosine Receptor

The A2A adenosine receptor (A2AR) has a more restricted distribution:

• Striatum: Highest density in the striatopallidal (indirect) pathway
• Olfactory tubercle: Dense expression
• Nucleus accumbens: Core and shell regions
• Cerebral cortex: Layer V pyramidal neurons
• Hippocampus: CA1 region
• Immune cells: Microglia and infiltrating leukocytes

A2B and A3 Receptors

These subtypes have more limited expression:

• A2B: Low expression, mainly in glial cells and blood vessels
• A3: Low CNS expression, higher in peripheral tissues

Neurophysiology

A1 Receptor Signaling

A1 receptors couple to Gi/o proteins, leading to:

• Inhibition of adenylate cyclase → decreased cAMP
• Activation of potassium channels → hyperpolarization
• Inhibition of calcium channels → reduced neurotransmitter release
• Activation of phospholipase C in some contexts

Physiological effects:

• Sedation and sleep promotion
• Neuroprotection against excitotoxicity
• Reduction of anxiety
• Anticonvulsant effects
• Modulation of pain perception

A2A Receptor Signaling

A2A receptors couple to Gs proteins, leading to:

• Stimulation of adenylate cyclase → increased cAMP
• Activation of protein kinase A
• Modulation of dopamine D2 receptor signaling
• Anti-inflammatory effects in glial cells

Physiological effects:

• Motor stimulation and arousal
• Wakefulness promotion
• Modulation of dopaminergic signaling
• Regulation of neuroinflammation
• Cognitive function modulation

Adenosine Tonus

Basal adenosine levels in the brain:

• Extracellular adenosine: 30-300 nM under normal conditions
• Activity-dependent increases: Up to 10-fold during neural activity
• Sleep-wake differences: Higher during wakefulness, lowest during REM sleep
• Metabolic regulation: ATP degradation product

Role in Neurodegenerative Diseases

Parkinson's Disease

A2A receptors play a particularly important role in PD:

• Striatal indirect pathway: A2A receptors are highly expressed on striatopallidal neurons
• D2 receptor antagonism: A2A activation reduces D2 receptor signaling
• Motor inhibition: Overactive indirect pathway causes bradykinesia
• A2A antagonists: Istradefylline (Nourianz) approved as add-on therapy

Therapeutic implications:

• Istradefylline improves OFF time in PD patients
• Caffeine (non-selective antagonist) shows neuroprotective effects
• A2A-D2 receptor heteromers as novel targets

Alzheimer's Disease

Adenosine receptors in AD:

• A1 receptor loss: Progressive decline correlates with cognitive impairment
• A2A receptor upregulation: Reactive astrocytes express more A2AR
• Amyloid-beta interaction: Aβ reduces adenosine transporter function
• Neuroinflammation: A2A receptors modulate microglial activation

Therapeutic potential:

• A2A antagonists may reduce amyloid pathology
• A1 agonists show neuroprotective effects in models
• Caffeine consumption associated with reduced AD risk

Huntington's Disease

• A2A receptor dysfunction: Altered striatal signaling
• Motor symptoms: A2A modulators show promise
• Neuroprotection: A2A antagonists reduce excitotoxicity

Amyotrophic Lateral Sclerosis

• A1 receptor decline: Correlates with disease progression
• A2A in neuroinflammation: Microglial A2AR modulation
• Therapeutic targeting: A2A agonists show mixed results

Stroke and Ischemia

• A1 neuroprotection: Preconditioning through A1 activation
• A2A in reperfusion: Modulates inflammatory response
• Therapeutic window: Timing critical for A2A modulation

Therapeutic Targeting

A2A Receptor Antagonists

Clinical use:

• Istradefylline (Nourianz): FDA-approved for PD
• Preladenant, SCH 420814: In development

Mechanism:

• Block A2A receptors in striatum
• Enhance dopaminergic signaling
• Reduce indirect pathway overactivity

A1 Receptor Modulators

Agonists:

• Capadenoson: In development for atrial fibrillation
• Neuroprotective in preclinical models

Antagonists:

• Investigated for sleep disorders
• Potential cognitive enhancement

Caffeine

• Non-selective adenosine receptor antagonist
• Associated with reduced PD and AD risk
• Cognitive enhancement at low doses
• Sleep disruption at high doses
• Cell-Types/Striatopallidal-Neurons — A2A-rich neurons in indirect pathway
• Cell-Types/Cortical-Pyramidal-Neurons — A2A-expressing cortical neurons
• Cell-Types/Hippocampal-Neurons — A1 receptor expression in hippocampus
• Mechanisms/Neuroinflammation — A2A modulation of glial function

Background

The study of Adenosine Receptor (A1 A2A) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
• [Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
• [Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Pathway Diagram

The following diagram shows the key molecular relationships involving Adenosine Receptor (A1/A2A) Neurons discovered through SciDEX knowledge graph analysis: